Philippe Menu Sells 2,800 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Insider sale: CFO Philippe Menu sold 2,800 shares on April 8 at $4.84 (and additional small blocks on April 6–9 and March 19) under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, trimming his stake by about 0.99% to 278,652 shares.
• Weak near‑term fundamentals: SOPH reported an EPS miss in March, continues to show negative margins and ROE, and trades around $4.70 with a market cap of about $322M, leaving valuation sensitive while analysts model negative EPS for the year.
• Mixed market sentiment: Institutional buyers like UBS and Akre materially increased positions recently and analysts’ average target is $7, but short interest rose ~20%, creating potential for volatility despite some buy‑side conviction.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 2,800 shares of the firm's stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $4.84, for a total value of $13,552.00. Following the transaction, the insider owned 278,652 shares of the company's stock, valued at approximately $1,348,675.68. This represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,152.94.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Trading Down 0.6%

Shares of SOPH traded down $0.03 during midday trading on Friday, hitting $4.70. 94,702 shares of the stock were exchanged, compared to its average volume of 184,971. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The stock has a fifty day simple moving average of $4.76 and a 200 day simple moving average of $4.68. The firm has a market cap of $321.90 million, a P/E ratio of -9.22 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The firm had revenue of $21.71 million for the quarter, compared to analysts' expectations of $21.20 million. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research reiterated a "buy" rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Guggenheim increased their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $7.00.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after buying an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. raised its stake in SOPHiA GENETICS by 16.4% in the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock valued at $682,000 after buying an additional 31,000 shares in the last quarter. Akre Capital Management LLC raised its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC acquired a new stake in SOPHiA GENETICS in the third quarter valued at $6,708,000. Finally, Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS in the third quarter valued at $48,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.